Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Low heart rate may dampen beta-blocker benefits in patients with heart failure, AF

10 Dec 2019

Low heart rate (HR) in patients with heart failure (HF) and atrial fibrillation (AF) receiving treatment with beta-blockers contributes to an increase in the risk of cardiovascular events, suggesting that a low HR may blunt the beneficial effects of the said drugs, a study has found.

The analysis included 97 HF patients with concomitant AF, grouped according to beta-blocker use (users, n=61; nonusers, n=36) and tertiles of discharge HR (lowest, <60 beats per minute [bpm]; middle, 61–70 bpm; highest, >71 bpm).

The primary endpoint of a composite of rehospitalization due to worsening of HF and all-cause mortality occurred in 37 beta-blocker users (61 percent) and 25 nonusers (69 percent) over a median follow-up of 772 days after discharge.

Multivariable Cox proportional hazard analysis revealed that the risk of the composite outcome was elevated in the lowest HR tertile among beta-blockers users vs the middle (hazard ratio [HR], 2.631, 95 percent confidence interval [CI], 1.078–6.421; p=0.034) and highest tertiles (HR, 2.876, 95 percent CI, 1.147–7.207; p=0.024).

In light of the findings, researchers pointed out that a low HR may lead to bradycardia that can, in turn, worsen HF. This underscores the need to take HR into account during the administration of beta-blockers in HF patients with AF.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.